Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Medicrea International SA Receives FDA Approval for PASS LP Systems
Medicrea International SA announced the FDA approval of the PASS LP system for the treatment of adolescent idiopathic scoliosis. The PASS LP is the lowest profile pedicle screw spinal fusion system available on the market and has been designed to address complex spinal pathologies making it specifically adapted to pediatric indications. The PASS LP thoraco-lumbar fixation system allows connection of the rod at a distance from the spine and performs a three-dimensional (3D) correction of the deformity through gentle and progressive stress distribution on all anchorages using the ST2R technique (Simultaneous Translation on 2 Rods). Through its derotation connectors & technique, the PASS LP offers a way to achieve correction of the deformity in all planes. Derotation in the coronal plane is obtained with no risk of screw ploughing or pull out while preserving sagittal balance, essential in the treatment of adolescent idiopathic scoliosis.
Latest Developments for Medicrea International SA
- Medicrea International SA Issues FY 2013 Operating Result Guidance
- Medicrea International SA Comments on H2 of FY 2012 Revenue Guidance
- Medicrea International SA's LigaPASSTM Announces FDA Approval and First Surgeries in the United States
- Medicrea International SA Issues FY 2012 Sales Guidance In Line with Analysts' Estimates
Latest Key Developments in Medical
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System
- Urban Ag Corp Announces It Has Entered Into The Final Stages Of Negotiations To Acquire Contractor Currently Generating $4,500,000 In Revenues
- HeartWare International Inc Receives Conditional Approval From FDA To Enroll Supplemental Patient Cohort In Destination Therapy Trial
- Share this
- Link this
- Digg this


Follow Reuters